Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Clin Exp Pathol. 2013 Dec 15;7(1):213-20. eCollection 2014.

Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.

Author information

1
Department of Pathology, Yokohama City University Graduate School of Medicine 3-9, Future, Kanazawaku, 236-0004, Yokohama, Japan.
2
Department of Surgery, Yokohama City University Graduate School of Medicine 3-9, Future, Kanazawaku, 236-0004, Yokohama, Japan.
3
Division of General Thoracic Surgery, Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital 6-16-1, Tomioka-higashi, Kanazawa-ku, 230-0051, Yokohama, Japan.

Abstract

Our previous studies identified important molecules involved in lung carcinogenesis through a comprehensive search for the downstream targets of oncogenic KRAS, and these findings suggested that an investigation into the downstream targets of oncogenic KRAS might represent a useful strategy for elucidating the common molecular bases of lung cancer. Among the downstream targets of oncogenic KRAS, a focus was placed on HDAC9, a member of the histone deacetylase family, in the present study because epigenetic modification of DNA or the histone proteins is known to play an important role in carcinogenesis. The immunohistochemical expression of HDAC9 was examined in surgically resected primary lung cancers (130 adenocarcinoma, 49 squamous cell carcinomas, one large cell carcinoma, and 6 small cell carcinomas) and potential associations between its expression level and pathologic factors were analyzed. The results showed that HDAC9 expression levels were lower in lung cancer cells than in non-tumor epithelial cells, and were also significantly lower in adenocarcinomas among the histological types. Moreover, HDAC9 expression levels were significantly lower in adenocarcinomas with lymphatic canal involvement. The restoration of HDAC9 in lung cancer cells losing its expression severely attenuated their growth activity in vitro. These results suggest that HDAC9 may be a suppressor and its downregulation might promote the progression process, especially in lung adenocarcinomas.

KEYWORDS:

HDAC9; KRAS; lung cancer

PMID:
24427341
PMCID:
PMC3885475
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center